EUVIMEDEUVIMED entdecken
Crossref

Extremely Low Dose of Erythropoiesis-Stimulating Agent May Be Associated with Increased Mortality in Hemodialysis Patients

Cheng-Wen Yang, Mei-Chen Lin, Kai-Hsiang Shu, Kuei-Tung Tung, Wan-Chuan Tsai, Ju-Yeh Yang, Mei-Fen Pai, Hon-Yen Wu, Yen-Ling Chiu, Yu-Sen Peng, Shih-Ping Hsu, Shi-Heng Wang und 1 weitere

American Journal of Nephrology · 2023

DOI: 10.1159/000529806 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Nephrology, 2023. Verfasst von Cheng-Wen Yang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Chien Shin hemodialysis center, New Taipei City, Taiwan. Hauptthemen laut MEDLINE: Hematinics, Erythropoietin. Die Arbeit nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Although high-dose erythropoiesis-stimulating agent (ESA) has been shown to increase mortality risk and adverse cardiovascular events in hemodialysis patients, the safety of extremely low-dose ESA is unclear.

Methods

We retrospectively analyzed the association between ESA dose and mortality in the monthly dosing range of 0–43,000 U of equivalent epoetin alfa in 304 Taiwan hemodialysis patients by using Cox proportional hazard model and cubic spline model.

Results

Compared with mean monthly ESA dose of 15,000–25,000 U (mean ± standard deviation 20,609 ± 2,662 U), monthly ESA dose of less than 15,000 U (mean ± standard deviation 7,413 ± 4,510 U) is associated with increased mortality. Monthly ESA dose of 25,001–43,000 U (mean ± standard deviation 31,160 ± 4,304 U) is not associated with higher mortality risk than monthly ESA dose of 15,000–25,000 U. The results were consistent in Cox proportional hazard models and cubic spline models. Subgroup analyses showed no significant heterogeneities among prespecified subgroups.

Conclusions

Extremely low dose of ESA in hemodialysis patients may be associated with increased mortality risk. Future studies are warranted to prove this association.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HematinicsErythropoietinHumansRetrospective StudiesErythropoiesisRenal DialysisEpoetin AlfaHemoglobins

Stichwörter der Autor:innen

Erythropoiesis-stimulating agentHemodialysisMortality

Substanzen

HematinicsEpoetin AlfaHemoglobinsErythropoietin

Autor:innen und Institutionen

  • Chien Shin hemodialysis center, New Taipei City, Taiwan.
  • National Center for Geriatrics and Welfare Research, National Health Research Institutes, Yunlin, Taiwan.
  • Department of Public Health, China Medical University, Taichung, Taiwan.
  • Division of Nephrology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
  • Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan.
  • Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei City, Taiwan.

Zitieren

APA

Yang, C. W., Lin, M. C., Shu, K. H., Tung, K. T., Tsai, W. C., Yang, J. Y., Pai, M. F., Wu, H. Y., Chiu, Y. L., Peng, Y. S., Hsu, S. P., Wang, S. H., & Pan, S. Y. (2023). Extremely Low Dose of Erythropoiesis-Stimulating Agent May Be Associated with Increased Mortality in Hemodialysis Patients. American Journal of Nephrology. https://doi.org/10.1159/000529806

Vancouver

Yang CW, Lin MC, Shu KH, Tung KT, Tsai WC, Yang JY, et al. Extremely Low Dose of Erythropoiesis-Stimulating Agent May Be Associated with Increased Mortality in Hemodialysis Patients. American Journal of Nephrology. 2023. doi:10.1159/000529806

BibTeX
@article{Yang2023,
  author = {Yang, Cheng-Wen and Lin, Mei-Chen and Shu, Kai-Hsiang and Tung, Kuei-Tung and Tsai, Wan-Chuan and Yang, Ju-Yeh and Pai, Mei-Fen and Wu, Hon-Yen and Chiu, Yen-Ling and Peng, Yu-Sen and Hsu, Shih-Ping and Wang, Shi-Heng and Pan, Szu-Yu},
  title = {Extremely Low Dose of Erythropoiesis-Stimulating Agent May Be Associated with Increased Mortality in Hemodialysis Patients},
  journal = {American Journal of Nephrology},
  year = {2023},
  doi = {10.1159/000529806}
}
Kostenlos starten →